Global Hemophilia Therapeutics Market Research Report 2022
Summary - A new market study, titled “Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate, Feiba), By Type of Hemophilia, By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement, Immune Tolerance Induction) Outlook 2022 ” has been featured on WiseGuyReports.
Hemophilia is an inherited bleeding disorder
that slows the blood clotting process. The people suffering from this condition
experience prolonged bleeding due to the lack of factors required for the
clotting of blood. According to World Federation of Hemophilia, about one in
10,000 people are born with this disease. Various types of drugs are injected
into the veins of patient in order to replace the clotting factors, which are
missing or low in number
As per RNCOS report “Global Hemophilia Therapeutics Market By
Drug (Advate, NovoSeven, Kogenate, Feiba), By Type of Hemophilia, By Treatment
(On-Demand, Prophylaxis), By Therapy (Replacement, Immune Tolerance Induction)
Outlook 2022”, the global hemophilia therapeutics market is anticipated to
witness a moderate growth during 2016-2022. This report provides a detailed
analysis of the current and future market scenario of the global hemophilia
therapeutics market. The report provides insight about the major drivers, such
as increasing awareness about hemophilia and its treatment options, grants and
tax credits, for the global hemophilia therapeutics market. Furthermore, few
challenges, such as manufacturing difficulties and low switching rate between
hemophilia medicines, which are hindering the growth of the global hemophilia
therapeutics market have also been mentioned in the report. In addition, the report
also highlights various opportunities available for growth of the global
hemophilia therapeutics market.
The global hemophilia therapeutics market has been segmented on the basis of
type of hemophilia, i.e. Hemophilia A, Hemophilia B, and Others. Hemophilia A
occupies the largest share in the global hemophilia therapeutics market, owing
to the highest prevalence of this type of hemophilia. Moreover, strong pipeline
of drugs for Hemophilia A is also helping its market to grow all across the
globe.
Furthermore, the global hemophilia therapeutics market has also been segmented
on the basis of type of treatment. According to the report, the treatment for
hemophilia can either be an on-demand treatment or a prophylaxis treatment.
Currently, on-demand treatment dominates the global hemophilia therapeutics
market, as patients usually go for treatment only when bleeding episodes occur.
However, prophylaxis is forecasted to be the fastest growing segment owing to
the requirement of better management of bleeding episodes.
Similarly, the market has also been segmented on the basis of
type of therapy into replacement therapy and immune tolerance induction
therapy. Apart from these types of therapies, efforts are also being made by
various pharmaceutical and biotech companies to develop gene therapy for the
treatment of hemophilia. Gene therapy is an evolving field which focuses on
correcting defective genes in order to cure genetic diseases, such as
hemophilia. Use of gene therapy for hemophilia treatment is a promising option,
as hemophilia is caused due to a single genetic defect. Even a minimal success
from this procedure can mean significant improvement in quality of life for
patients. Numerous companies, such as BioMarin Pharmaceuticals and uniQure, are
carrying out clinical trials for gene therapies for the treatment of
hemophilia. Hence, gene therapy presents great opportunities for the growth of
global hemophilia therapeutics market in the coming years.
Based on geography, the report divides the market into North
America, Europe, and Asia-Pacific. In 2016, North America accounted for the
largest share in the global hemophilia therapeutics market. Moreover, the
report also highlights various mergers and acquisitions taking place in the
global hemophilia therapeutics industry. The pipeline of hemophilia drugs have
also been mentioned in the report.
The last section of the report discusses about the prominent
players in global hemophilia therapeutics market. A brief business overview and
financial information about each of these players has been provided, along with
their product portfolios and product pipeline. The recent developments of every
player have also been presented in the report. Overall, the research contains
exhaustive information that will help clients in formulating market strategies
and assessing opportunity areas in the global hemophilia therapeutics market.
FOR MORE
DETAILS: https://www.wiseguyreports.com/reports/1706518-global-hemophilia-therapeutics-market-by-drug-advate-novoseven-kogenate-feiba-by
About Us:
Wise Guy
Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers
premium progressive statistical surveying, market research reports, analysis
& forecast data for industries and governments around the globe.
Contact Us:
NORAH
TRENT
Ph:
+162-825-80070
(US)
Ph: +44 203
500 2763 (UK)
Comments
Post a Comment